LETTER TO THE EDITOR - Letter to the editor regarding - association of CXCL16 in aseptic loosening following total hip arthroplasty and its effect on bone metabolism, a case-control study

Sep 30, 2026

Letter to the editor responding to a case-control study on CXCL16 in aseptic loosening after total hip arthroplasty. The authors commend the reported correlation between CXCL16 overexpression and RANKL/OPG imbalance, while highlighting gaps for clinical translation: need for non-invasive circulating biomarker validation, further development of prosthetic material and immunomodulatory implant strategies, consideration of socioeconomic cost impacts, and unanswered spatiotemporal dynamics. They propose biomarker thresholds, longitudinal monitoring, multi-omics specificity, and AI-enabled modeling to support precision prevention.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Letter to the editor

Clinical translation gaps

Acknowledgements

Authors’ contributions

Disclosure statement

Funding

Data availability statement

References

AnnAls of Medicine 2026, Vol. 58, no. 1, 2610547 [https://doi.org/10.1080/07853890.2025.2610547](https://doi.org/10.1080/07853890.2025.2610547) LETTER TO THE EDITOR Letter to the editor regarding: ‘association of CXCL16 in aseptic loosening following total hip arthroplasty and its effect on bone metabolism: a case-control study’ We commend Zhu et al. for establishing a robust correlation between CXCL16 overexpression and RANKL/ OPG imbalance in aseptic loosening (AL) [1] . Their work provides valuable mechanistic insights into macrophage-driven osteoclast activation. However, three critical gaps limit clinical translation and warrant scholarly dialogue. First, the absence of non-invasive biomarker validation restricts CXCL16’s utility in early AL detection. While tissue-based correlations are compelling, circulating CXCL16 levels remain unquantified. Serum/plasma quantification via longitudinal cohort studies—correlated with PET-CT osteolysis signatures—is essential to establish diagnostic thresholds and dynamic monitoring protocols. Integrating multi-omics (e.g. CXCL16 + miR-451a synergy in osteolysis regulation) could enhance specificity beyond inflammatory confounders. Second, prosthetic material opportunities were underdeveloped. The observed lower CXCL16 expression with ceramic couplings suggests implant surface engineering could preemptively modulate macrophage polarization. Nano-textured interfaces promoting anti-inflammatory M2c phenotypes merit exploration to disrupt CXCL16-RANKL crosstalk. Concurrently, repurposing anti-CXCL16 monoclonal antibodies for high-risk patients might extend prosthesis longevity—a hypothesis testable through adaptive trial designs. Third, socioeconomic dimensions were overlooked. Aseptic loosening is the most commonly reported reason for revision surgery, imposing a substantial financial burden on patients [2] . Embedding cost-effectiveness analyses within biomarker validation studies (e.g. CXCL16 screening vs. revision expenses) would align discovery with value-based orthopedics. Federated analysis of joint registries could further reveal disparities in AL burden related to demographics or access barriers, guiding equitable prevention strategies. Spatiotemporal dynamics of CXCL16 also remain unaddressed. Spatial transcriptomics mapping peri-implant osteolytic niches and graph neural networks modeling wear particle kinetics could unveil CXCL16’s role in biomechanical failure cascades. Such AI-driven approaches might predict individualized AL trajectories beyond static correlations. In summary, elevating CXCL16 from a biomarker candidate to a clinical tool requires validating circulatory assays, pioneering immunomodulatory implants, and integrating health economics. This trifecta could transition AL management from reactive revision to precision prevention, ultimately enhancing global jointarthroplasty sustainability. Acknowledgements We acknowledge the original authors for their significant contribution to this research. All authors contributed to the study conception and design. Writing - original draft, Resources, Investigation were performed by Sheng Zheng and Jinjin Luo; Writing - review and editing, Conceptualization were performed by Yong Zhu. Authors’ contributions CRediT: Sheng Zheng: Investigation, Resources, Writing – original draft; Jinjin Luo: Investigation, Resources, Writing – original draft; Yong Zhu: Conceptualization, Writing – review & editing. Disclosure statement No potential conflict of interest was reported by the author(s) . Funding The authors reported there is no funding associated with the work featured in this article. 2 S. ZHENG ET AL. Data availability statement Data sharing is not applicable to this article as no data were created or analysed in this study. References [1] Zhu L, Wang K, Li P, et al. Association of CXCL16 in aseptic loosening following total hip arthroplasty and its effect on bone metabolism: a ca

FAQs

What did the letter commend about Zhu et al.’s study?

The letter commends Zhu et al. for establishing a robust correlation between CXCL16 overexpression and RANKL/OPG imbalance in aseptic loosening and for providing mechanistic insights into macrophage-driven osteoclast activation.

Why is non-invasive biomarker validation emphasized?

The letter argues that tissue-based correlations do not yet establish CXCL16’s clinical utility for early detection, because circulating CXCL16 levels were not quantified. It calls for serum/plasma measurements in longitudinal cohorts and diagnostic threshold validation.

What additional areas does the letter suggest to improve translation?

It highlights underdeveloped prosthetic material opportunities, recommends exploring immunomodulatory implant strategies (e.g., interface engineering or anti-CXCL16 antibodies), notes overlooked health-economic and socioeconomic dimensions, and proposes spatiotemporal mapping and AI modeling to understand CXCL16’s role in failure cascades.

Sep 30, 2026

Uploaded by วิน